Press Releases

Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting

Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care

Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines

Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Panbela Provides Business Update and Reports Q3 2021 Financial Results

Panbela Schedules Conference Call on Nov 10 to Report Q3 2021 Financial Results

Panbela to Present at Upcoming Investor Conferences

H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23

Panbela Provides Business Update and Reports Q2 2021 Financial Results

Panbela Announces Issuance of key U.S. Patent; Patent is for Claims of a Novel Process for the Production of SBP-101

Patent developed in collaboration with Syngene International Ltd

Panbela Schedules Conference Call on August 11 to Report 2021 Second Quarter Financial Results